Table 1

Baseline demographic and anthropomorphic characteristics of base study treatment groups

ParameterPlacebo(n = 114)Omarigliptin once weekly
0.25 mg(n = 113)1 mg(n = 115)3 mg(n = 114)10 mg(n = 115)25 mg(n = 114)
Age, years55.9 ± 8.454.3 ± 8.955.7 ± 8.555.3 ± 8.554.4 ± 10.055.1 ± 8.8
Male, %65 (57.0)65 (57.5)67 (58.3)65 (57.0)56 (48.7)69 (60.5)
Race
 White64 (56.1)60 (53.1)70 (60.9)70 (61.4)64 (55.7)62 (54.4)
 Asian32 (28.1)33 (29.2)33 (28.7)27 (23.7)30 (26.1)30 (26.3)
 Multiracial10 (8.8)6 (5.3)4 (3.5)5 (4.4)8 (7.0)12 (10.5)
 American Indian or Alaska Native4 (3.5)8 (7.1)6 (5.2)2 (1.8)9 (7.8)3 (2.6)
 Black or African American3 (2.6)5 (4.4)2 (1.7)8 (7.0)3 (2.6)7 (6.1)
 Native Hawaiian or other Pacific Islander1 (0.9)1 (0.9)0 (0.0)2 (1.8)1 (0.9)0 (0.0)
Ethnicity
 Hispanic or Latino34 (29.8)30 (26.5)35 (30.4)24 (21.1)31 (27.0)37 (32.5)
 Not Hispanic or Latino80 (70.2)83 (73.5)80 (69.6)90 (78.9)84 (73.0)77 (67.5)
Body weight, kg82.1 ± 20.482.0 ± 18.882.5 ± 17.784.1 ± 17.282.3 ± 16.580.5 ± 17.5
BMI, kg/m229.6 ± 5.329.7 ± 5.529.9 ± 5.330 ± 5.130.4 ± 5.229.2 ± 5.2
Type 2 diabetes duration, years5.8 ± 4.64.8 ± 4.25.3 ± 4.35.4 ± 3.95.1 ± 4.65.9 ± 5.2
Prior AHA use58 (50.9)59 (52.2)59 (51.3)59 (51.8)59 (51.3)59 (51.8)
HbA1c, % 8.1 ± 0.98.1 ± 0.98.0 ± 0.97.9 ± 0.98.0 ± 0.98.1 ± 1.0
 Range6.6–10.46.0–11.36.0–10.46.7–11.76.4–10.76.4–11.0
HbA1c, mmol/mol65.0 ± 9.865.2 ± 10.163.8 ± 9.463.2 ± 9.564.4 ± 9.465.5 ± 11.1
 Range48.6–90.242.1–100.042.1–90.249.7–104.4 46.4–93.446.4–96.7
2-h PMG, mmol/L13.4 ± 4.012.7 ± 3.512.7 ± 3.613.0 ± 4.512.9 ± 4.013.6 ± 4.6
FPG, mmol/L9.6 ± 2.49.5 ± 2.59.4 ± 2.49.4 ± 2.49.3 ± 2.19.7 ± 2.6
  • Data are expressed as mean ± SD or as n (%), unless otherwise indicated.

  • To convert PMG or FPG in mmol/L to mg/dL, multiply by 18.